Dansk Hypertensionsselskab
Tirzepatide is the first antidiabetic drug that is a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Retatrutide contribution includes improved insulin sensitivity (GLP-1 and GIP), reduced liver fat (glucagon), improved lipid profiles (all three receptors), and reduced blood pressure (weight loss effect)
By mimicking the bodys natural incretin hormones, Tirzepatide helps support insulin secretion in response to elevated blood glucose levels while simultaneously reducing appetite and slowing gastric emptying
However, sometimes it may indicate an underlying health condition or the beginning of anaphylactic shock
This extraordinary sensitivity is mediated by the activation of the mechanosensitive transient receptor potential cation channel subfamily M member 7 (TRPM7), which in turn triggers calcium ions (Ca 2+ ) influx, thereby promoting a thicker actomyosin cortex [50]